Status:
COMPLETED
Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery
Lead Sponsor:
University College, London
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Coronary heart disease (CHD) is the leading cause of death in the UK, accounting for 124,000 deaths (2006) and costing the UK economy over £7.9 billion a year. Patients with severe CHD are usually tre...
Eligibility Criteria
Inclusion
- Patients undergoing CABG with or without valve surgery using blood cardioplegia
- Patients aged 18 years and above
- Patients with an additive Euroscore greater than or equal to 5
Exclusion
- Cardiogenic shock
- Cardiac arrest on current admission
- Pregnancy
- Significant peripheral arterial disease affecting the upper limbs
- Patients with significant hepatic dysfunction (Prothrombin\>2.0 ratio)
- Patients with significant pulmonary disease (FEV1\<40% predicted)
- Patients with known renal failure with a GFR\<30 mL/min/1.73 m2
- Patients on glibenclamide or nicorandil, as these medications may interfere with RIC
- Patients recruited into another study which may impact on the ERICCA study
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
1612 Patients enrolled
Trial Details
Trial ID
NCT01247545
Start Date
November 1 2010
End Date
March 1 2015
Last Update
May 29 2015
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Essex Cardiothoracic Centre
Basildon, Essex, United Kingdom
2
Royal Sussex County Hospital
Brighton, Sussex, United Kingdom
3
Blackpool Victoria Hospital
Blackpool, United Kingdom
4
Papworth Hospital
Cambridge, United Kingdom